HER2 Peptide and T Cell Response in Cancer Immunotherapy
Author Information
Author(s): Sotiriadou R, Perez S A, Gritzapis A D, Sotiropoulou P A, Echner H, Heinzel S, Mamalaki A, Pawelec G, Voelter W, Baxevanis C N, Papamichail M
Primary Institution: Cancer Immunology Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
Hypothesis
HER2(776–788) is a broadly presented MHC class II-restricted T cell epitope that can induce CD4+ T cell responses.
Conclusion
The HER2(776–788) peptide can stimulate CD4+ T cell responses and is presented by multiple HLA-DR alleles, suggesting its potential in cancer immunotherapy.
Supporting Evidence
- HER2(776–788) peptide induced specific T cell responses.
- The peptide was presented by multiple HLA-DR alleles.
- Clones recognized both melanoma and breast cancer cell lines.
Takeaway
Scientists found a piece of a protein from cancer cells that helps the immune system recognize and fight cancer better.
Methodology
The study involved generating and characterizing CD4+ T cell clones that recognize the HER2(776–788) peptide and testing their responses with dendritic cells.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website